Skip to main content
. Author manuscript; available in PMC: 2016 Oct 15.
Published in final edited form as: J Immunol. 2016 Mar 4;196(8):3354–3363. doi: 10.4049/jimmunol.1502687

Figure 1. Inflation is seen following immunisation with Ad-LacZ vectors utilising different transgenic promoters.

Figure 1

C57BL/6 mice were immunised with Ad-LacZ constructs, which had either of an HCMV (short) promoter (2×109 iu/mouse), RSV (Rous sarcoma virus) promoter (1×109 iu/mouse) or an EF1-α (mammalian elongation factor 1-α) promoter (1×109 iu/mouse). A control group of naïve mice has been tested alongside all constructs. (A) Shows the tetramer-specific responses for D8V/βgal96 and I8V/βgal497, which were tracked in blood over a time course of day 14, 21, 50 and 100-post immunisation. The naïve control background responses are undetectable. (B) Demonstrates representative phenotyping of the D8V-specific populations in blood from day 100 immunised mice. (C) Demonstrates the distribution data at day 100-post immunisation. Individual D8V and I8V-specific responses are shown for each of the Ad-LacZ constructs with varying promoters in the liver, lung and spleen. (D) Demonstrates the functional (IFNγ and TNFα production in ICS) data at day 100-post immunisation (in splenocytes). (E) Demonstrates comparison of a long and short HCMV promoter (immunised at 1×109 and 2×109 iu/mouse respectively), with D8V tetramer-specific responses in blood shown at day 21 and 50-post immunisation (n=4/group with results showing the mean ± SEM. All work has been performed twice independently showing the same results).